Close Menu

Molecular Diagnostics

News on lab-developed tests and emerging diagnostic technologies.

Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.

The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.

The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.

 

Sep
24

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.